Mortality impact of less-than-standard therapy in older breast cancer patients

The purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus radiation therapy (RT), mastectomy, and the receipt of adjuvant tamoxifen in a large population-based cohort of older women with early-stage disea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of the American College of Surgeons Ročník 206; číslo 1; s. 66
Hlavní autoři: Yood, Marianne Ulcickas, Owusu, Cynthia, Buist, Diana S M, Geiger, Ann M, Field, Terry S, Thwin, Soe Soe, Lash, Timothy L, Prout, Marianne N, Wei, Feifei, Quinn, Virginia P, Frost, Floyd J, Silliman, Rebecca A
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.01.2008
Témata:
ISSN:1879-1190, 1879-1190
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus radiation therapy (RT), mastectomy, and the receipt of adjuvant tamoxifen in a large population-based cohort of older women with early-stage disease. This cohort study was conducted within six US integrated health-care delivery systems. Automated administrative databases, medical records, and tumor registries were used to identify women aged 65 years or older who received BCS or mastectomy to treat stage I or II breast cancer diagnosed from January 1, 1990, through December 31, 1994. We compared cause-specific 10-year mortality rates across treatment categories by fitting Cox proportional hazards models adjusted for demographics and tumor characteristics. We identified 1,837 women having operations for stage I or II breast cancer. Compared with women receiving mastectomy, those receiving BCS without RT were twice as likely to die of breast cancer (adjusted hazards ratio [HR]=2.19, 95% confidence interval [CI], 1.51 to 3.18). Breast cancer mortality rates were similar between women receiving BCS plus RT and women receiving mastectomy (adjusted HR=1.08, 95% CI, 0.79 to 1.48). In the subset of 886 chemotherapy-naive women treated with tamoxifen, those treated with tamoxifen for less than 1 year had a substantially higher breast cancer mortality rate than those exposed 5 years or more (adjusted HR=6.26, 95% CI, 3.10 to 12.64). Our findings indicate that older women receiving BCS alone have higher rates of breast cancer death than those receiving BCS + RT or mastectomy and that the survival benefit from tamoxifen increases with increasing duration of treatment.
AbstractList The purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus radiation therapy (RT), mastectomy, and the receipt of adjuvant tamoxifen in a large population-based cohort of older women with early-stage disease.BACKGROUNDThe purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus radiation therapy (RT), mastectomy, and the receipt of adjuvant tamoxifen in a large population-based cohort of older women with early-stage disease.This cohort study was conducted within six US integrated health-care delivery systems. Automated administrative databases, medical records, and tumor registries were used to identify women aged 65 years or older who received BCS or mastectomy to treat stage I or II breast cancer diagnosed from January 1, 1990, through December 31, 1994. We compared cause-specific 10-year mortality rates across treatment categories by fitting Cox proportional hazards models adjusted for demographics and tumor characteristics.STUDY DESIGNThis cohort study was conducted within six US integrated health-care delivery systems. Automated administrative databases, medical records, and tumor registries were used to identify women aged 65 years or older who received BCS or mastectomy to treat stage I or II breast cancer diagnosed from January 1, 1990, through December 31, 1994. We compared cause-specific 10-year mortality rates across treatment categories by fitting Cox proportional hazards models adjusted for demographics and tumor characteristics.We identified 1,837 women having operations for stage I or II breast cancer. Compared with women receiving mastectomy, those receiving BCS without RT were twice as likely to die of breast cancer (adjusted hazards ratio [HR]=2.19, 95% confidence interval [CI], 1.51 to 3.18). Breast cancer mortality rates were similar between women receiving BCS plus RT and women receiving mastectomy (adjusted HR=1.08, 95% CI, 0.79 to 1.48). In the subset of 886 chemotherapy-naive women treated with tamoxifen, those treated with tamoxifen for less than 1 year had a substantially higher breast cancer mortality rate than those exposed 5 years or more (adjusted HR=6.26, 95% CI, 3.10 to 12.64).RESULTSWe identified 1,837 women having operations for stage I or II breast cancer. Compared with women receiving mastectomy, those receiving BCS without RT were twice as likely to die of breast cancer (adjusted hazards ratio [HR]=2.19, 95% confidence interval [CI], 1.51 to 3.18). Breast cancer mortality rates were similar between women receiving BCS plus RT and women receiving mastectomy (adjusted HR=1.08, 95% CI, 0.79 to 1.48). In the subset of 886 chemotherapy-naive women treated with tamoxifen, those treated with tamoxifen for less than 1 year had a substantially higher breast cancer mortality rate than those exposed 5 years or more (adjusted HR=6.26, 95% CI, 3.10 to 12.64).Our findings indicate that older women receiving BCS alone have higher rates of breast cancer death than those receiving BCS + RT or mastectomy and that the survival benefit from tamoxifen increases with increasing duration of treatment.CONCLUSIONSOur findings indicate that older women receiving BCS alone have higher rates of breast cancer death than those receiving BCS + RT or mastectomy and that the survival benefit from tamoxifen increases with increasing duration of treatment.
The purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus radiation therapy (RT), mastectomy, and the receipt of adjuvant tamoxifen in a large population-based cohort of older women with early-stage disease. This cohort study was conducted within six US integrated health-care delivery systems. Automated administrative databases, medical records, and tumor registries were used to identify women aged 65 years or older who received BCS or mastectomy to treat stage I or II breast cancer diagnosed from January 1, 1990, through December 31, 1994. We compared cause-specific 10-year mortality rates across treatment categories by fitting Cox proportional hazards models adjusted for demographics and tumor characteristics. We identified 1,837 women having operations for stage I or II breast cancer. Compared with women receiving mastectomy, those receiving BCS without RT were twice as likely to die of breast cancer (adjusted hazards ratio [HR]=2.19, 95% confidence interval [CI], 1.51 to 3.18). Breast cancer mortality rates were similar between women receiving BCS plus RT and women receiving mastectomy (adjusted HR=1.08, 95% CI, 0.79 to 1.48). In the subset of 886 chemotherapy-naive women treated with tamoxifen, those treated with tamoxifen for less than 1 year had a substantially higher breast cancer mortality rate than those exposed 5 years or more (adjusted HR=6.26, 95% CI, 3.10 to 12.64). Our findings indicate that older women receiving BCS alone have higher rates of breast cancer death than those receiving BCS + RT or mastectomy and that the survival benefit from tamoxifen increases with increasing duration of treatment.
Author Geiger, Ann M
Thwin, Soe Soe
Field, Terry S
Frost, Floyd J
Prout, Marianne N
Buist, Diana S M
Lash, Timothy L
Silliman, Rebecca A
Yood, Marianne Ulcickas
Wei, Feifei
Owusu, Cynthia
Quinn, Virginia P
Author_xml – sequence: 1
  givenname: Marianne Ulcickas
  surname: Yood
  fullname: Yood, Marianne Ulcickas
  organization: Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA
– sequence: 2
  givenname: Cynthia
  surname: Owusu
  fullname: Owusu, Cynthia
– sequence: 3
  givenname: Diana S M
  surname: Buist
  fullname: Buist, Diana S M
– sequence: 4
  givenname: Ann M
  surname: Geiger
  fullname: Geiger, Ann M
– sequence: 5
  givenname: Terry S
  surname: Field
  fullname: Field, Terry S
– sequence: 6
  givenname: Soe Soe
  surname: Thwin
  fullname: Thwin, Soe Soe
– sequence: 7
  givenname: Timothy L
  surname: Lash
  fullname: Lash, Timothy L
– sequence: 8
  givenname: Marianne N
  surname: Prout
  fullname: Prout, Marianne N
– sequence: 9
  givenname: Feifei
  surname: Wei
  fullname: Wei, Feifei
– sequence: 10
  givenname: Virginia P
  surname: Quinn
  fullname: Quinn, Virginia P
– sequence: 11
  givenname: Floyd J
  surname: Frost
  fullname: Frost, Floyd J
– sequence: 12
  givenname: Rebecca A
  surname: Silliman
  fullname: Silliman, Rebecca A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18155570$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1LxDAYhIMo7of-BakXb61v2qZpj7L4Bate9FzeJm_dLmlak_Sw_96KKwgDMwMPc5gVO7WDJcauOSQceHG7T_bYq8EYP7nPJAWQyY-4OGFLXsoq5ryC0395wVbe7wG4hKo4ZwteciGEhCV7fRlcQNOFQ9T1I6oQDW1kyPs47NDGPqDV6HQUduRwnCEbDUaTixpH6EOk0Kq5jRg6ssFfsLMWjafLo6_Zx8P9--Yp3r49Pm_utrHKCwhxCU3WFHnRUi5FU5CGVCme8rzNJEDVQK4yrmXWZqQaXpbYEuoyFxqFliWqdM1ufndHN3xN5EPdd16RMWhpmHwt5zOqXGQzeHUEp6YnXY-u69Ed6r8H0m-f5GRO
CitedBy_id crossref_primary_10_2217_cer_14_83
crossref_primary_10_1245_s10434_014_4290_5
crossref_primary_10_4048_jbc_2024_0190
crossref_primary_10_1016_j_ctim_2012_04_002
crossref_primary_10_1093_jnci_djp038
crossref_primary_10_1245_s10434_012_2825_1
crossref_primary_10_1200_JCO_2016_67_7336
crossref_primary_10_1016_j_jval_2013_02_006
crossref_primary_10_1177_000313481708300842
crossref_primary_10_2217_ahe_11_24
crossref_primary_10_1016_j_ejso_2020_10_008
crossref_primary_10_1093_annonc_mdv251
crossref_primary_10_3390_ijms232113604
crossref_primary_10_1245_s10434_013_3374_y
crossref_primary_10_1136_bmjopen_2020_041626
crossref_primary_10_1007_s11764_009_0107_0
crossref_primary_10_1080_03630242_2015_1061095
crossref_primary_10_1007_s00129_010_2642_1
crossref_primary_10_1016_j_ijsu_2014_08_344
crossref_primary_10_1245_s10434_021_09777_3
crossref_primary_10_1016_j_clbc_2023_01_012
crossref_primary_10_1007_s00520_012_1450_7
crossref_primary_10_1245_s10434_018_6617_0
crossref_primary_10_1007_s10549_020_05684_5
crossref_primary_10_1007_s00520_022_07156_6
crossref_primary_10_1016_j_ejso_2015_01_028
crossref_primary_10_1245_s10434_022_12237_1
crossref_primary_10_1590_0102_311X00114214
crossref_primary_10_1590_1413_81232015203_07982014
crossref_primary_10_1016_j_critrevonc_2009_09_007
crossref_primary_10_1016_j_surg_2024_08_045
crossref_primary_10_1038_bjc_2013_116
crossref_primary_10_1038_s41598_019_40072_0
crossref_primary_10_1016_j_clbc_2015_02_005
crossref_primary_10_1097_MLR_0000000000001019
crossref_primary_10_1007_s10549_019_05353_2
crossref_primary_10_1136_bmjopen_2022_069971
crossref_primary_10_1016_j_clbc_2024_05_002
crossref_primary_10_3390_jpm5030229
crossref_primary_10_1007_s10549_020_05912_y
crossref_primary_10_1200_JCO_2014_58_3062
crossref_primary_10_1093_tbm_ibx061
crossref_primary_10_1200_JCO_2008_18_3459
crossref_primary_10_1007_s00520_015_2698_5
crossref_primary_10_1016_j_ctrv_2021_102264
crossref_primary_10_1038_bjc_2013_464
crossref_primary_10_1016_j_ijsu_2016_05_045
crossref_primary_10_1080_07347332_2021_1955318
crossref_primary_10_1148_rg_220166
crossref_primary_10_1002_cncr_25821
crossref_primary_10_1007_s10549_013_2499_9
crossref_primary_10_1038_sj_bjc_6604758
crossref_primary_10_1245_s10434_021_09839_6
crossref_primary_10_1200_JCO_2009_25_9655
crossref_primary_10_1007_s00520_022_06848_3
crossref_primary_10_1002_cncr_34409
crossref_primary_10_1200_EDBK_156682
crossref_primary_10_14694_EdBook_AM_2013_33_271
crossref_primary_10_1016_j_jclinepi_2009_03_001
crossref_primary_10_1002_cncr_26505
crossref_primary_10_1016_j_ejca_2018_03_014
crossref_primary_10_1200_JCO_2008_19_4928
crossref_primary_10_2147_PPA_S296747
crossref_primary_10_1245_s10434_016_5368_z
crossref_primary_10_2217_pgs_12_29
crossref_primary_10_1016_j_surg_2022_05_026
crossref_primary_10_1007_s10552_012_0115_7
crossref_primary_10_2217_bmt_14_48
crossref_primary_10_1016_j_breast_2025_104476
crossref_primary_10_1148_radiol_14140209
crossref_primary_10_1016_j_amjsurg_2020_12_029
crossref_primary_10_1093_bjsopen_zrae040
crossref_primary_10_1186_1471_2482_13_S2_S2
crossref_primary_10_1002_cncr_32976
crossref_primary_10_1002_jso_21799
crossref_primary_10_1016_j_clinimag_2025_110467
crossref_primary_10_1016_j_suronc_2009_07_004
crossref_primary_10_1002_cncr_31241
crossref_primary_10_1245_s10434_013_2918_5
crossref_primary_10_1245_s10434_022_12133_8
crossref_primary_10_1186_2193_1801_3_282
crossref_primary_10_1007_s10549_010_1132_4
crossref_primary_10_1158_1940_6207_CAPR_11_0442
crossref_primary_10_1007_s10880_020_09750_4
crossref_primary_10_1586_era_09_67
crossref_primary_10_1111_j_1532_5415_2009_02506_x
crossref_primary_10_1186_1471_2407_13_434
crossref_primary_10_1200_JCO_2009_25_9796
crossref_primary_10_1007_s12529_020_09908_2
crossref_primary_10_1200_JCO_2010_33_3179
crossref_primary_10_1136_bmjopen_2021_052146
crossref_primary_10_1007_s12032_015_0599_6
crossref_primary_10_1089_whr_2020_0094
crossref_primary_10_1111_jep_12819
crossref_primary_10_3389_fonc_2023_1287253
crossref_primary_10_1007_s10549_013_2710_z
crossref_primary_10_1158_1940_6207_CAPR_13_0389
crossref_primary_10_1016_j_clbc_2019_01_007
crossref_primary_10_1080_20476965_2018_1440925
crossref_primary_10_1186_s40814_022_00985_6
crossref_primary_10_3390_cancers16193317
crossref_primary_10_1016_j_clon_2008_11_012
crossref_primary_10_1097_COC_0000000000000314
crossref_primary_10_1002_pds_4012
crossref_primary_10_1016_j_ijrobp_2017_01_228
crossref_primary_10_1007_s10549_013_2517_y
crossref_primary_10_1200_JCO_2008_19_2419
crossref_primary_10_1093_annonc_mdr330
crossref_primary_10_1007_s10549_013_2720_x
crossref_primary_10_1016_j_ejso_2018_02_011
crossref_primary_10_1002_cncr_23447
crossref_primary_10_1007_s10549_020_05748_6
crossref_primary_10_1093_jnci_dju319
crossref_primary_10_1007_s11764_021_01114_7
crossref_primary_10_1007_s00066_012_0253_6
crossref_primary_10_1016_S0960_9776_11_70287_9
crossref_primary_10_1371_journal_pone_0263104
crossref_primary_10_1016_j_ijsu_2013_05_032
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jamcollsurg.2007.07.015
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 1879-1190
ExternalDocumentID 18155570
Genre Multicenter Study
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R01 CA093772
– fundername: NCI NIH HHS
  grantid: U19 CA079689
GroupedDBID ---
--K
--M
-RU
.55
.GJ
.~1
0R~
1B1
1CY
1KJ
1P~
1~.
1~5
29L
2QL
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6PF
7-5
71M
8P~
AAAAV
AABNK
AAEDT
AAEDW
AAGIX
AAIKJ
AAIQE
AAJCS
AAKOC
AALRI
AAOAW
AAQFI
AAQOH
AAQQT
AAQXK
AAWTL
AAXUO
AAYWO
ABBQC
ABFRF
ABJNI
ABMAC
ABMZM
ABOCM
ABPPZ
ABPXF
ABWVN
ABXDB
ABXYN
ABZZY
ACBMB
ACDAQ
ACGFO
ACGFS
ACILI
ACIUM
ACLDA
ACRPL
ACVFH
ACXJB
ACZKN
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADSXY
AEBDS
AEFWE
AEKER
AENEX
AEUPX
AEVXI
AFBFQ
AFEXH
AFFNX
AFNMH
AFPUW
AFTJW
AGHFR
AGQPQ
AGUBO
AGYEJ
AHOMT
AHQNM
AHQVU
AI.
AIGII
AITUG
AJCLO
AJNWD
AJRQY
AJZMW
AKCTQ
AKRWK
ALKUP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANZVX
AOQMC
ASPBG
AVWKF
AZFZN
BKOJK
BLXMC
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EEVPB
EIF
EJD
EO9
EP2
EP3
ERAAH
EX3
F5P
FCALG
FDB
FEDTE
FGOYB
FIRID
FNPLU
GBLVA
HVGLF
HZ~
IH2
IHE
J1W
J5H
KOM
L7B
LXL
LXN
M41
MO0
N4W
N9A
NPM
O-L
O9-
OAUVE
OHT
OVD
OZT
P-8
P-9
P2P
PC.
PQQKQ
Q38
R2-
RIG
RLZ
ROL
RPZ
SDF
SDG
SEL
SES
SEW
SJN
SPCBC
SSZ
TEORI
UHB
UV1
UXK
VH1
WH7
WOW
X7M
ZGI
ZRR
ZXP
~G-
7X8
EFLBG
~HD
ID FETCH-LOGICAL-c460t-80b3b646fe475b6ed02cc1214f37009b04c31d73f3ecb188afead845da5d78ac2
IEDL.DBID 7X8
ISICitedReferencesCount 137
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000252109200009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1879-1190
IngestDate Sun Sep 28 10:00:11 EDT 2025
Tue Aug 05 11:35:18 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-80b3b646fe475b6ed02cc1214f37009b04c31d73f3ecb188afead845da5d78ac2
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 18155570
PQID 70159453
PQPubID 23479
ParticipantIDs proquest_miscellaneous_70159453
pubmed_primary_18155570
PublicationCentury 2000
PublicationDate 2008-Jan
20080101
PublicationDateYYYYMMDD 2008-01-01
PublicationDate_xml – month: 01
  year: 2008
  text: 2008-Jan
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of the American College of Surgeons
PublicationTitleAlternate J Am Coll Surg
PublicationYear 2008
References 18501828 - J Am Coll Surg. 2008 Jun;206(3):1240
References_xml – reference: 18501828 - J Am Coll Surg. 2008 Jun;206(3):1240
SSID ssj0017096
Score 2.2968996
Snippet The purpose of this study was to compare the rates of all-cause and breast cancer-specific mortality after breast-conserving surgery (BCS) only, BCS plus...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 66
SubjectTerms Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal - therapeutic use
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Female
Follow-Up Studies
Humans
Mastectomy - methods
Neoplasm Staging
Proportional Hazards Models
Radiotherapy, Adjuvant - methods
Retrospective Studies
Survival Rate - trends
Tamoxifen - therapeutic use
Treatment Outcome
United States - epidemiology
Title Mortality impact of less-than-standard therapy in older breast cancer patients
URI https://www.ncbi.nlm.nih.gov/pubmed/18155570
https://www.proquest.com/docview/70159453
Volume 206
WOSCitedRecordID wos000252109200009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB5WV8SLD3ytzwheg02TNC0IIuLiZcseFPa2JGkqirbrdtff76QP9iQehNJTA2WYzHzMfDMfwLVJYsswytHIt3YFyxnVodVUaczvNrIJ47YWm1BpGk8mybgHt90sjKdVdjGxDtRZaX2N_EZh3kqE5HezL-o1o3xvtRXQWIM-RyDjCV1qsuohqKBW5_Jy2pRh3tuEqxW7611_ekNXy_lru8cQHyZ_x5l1vhnu_O9Pd2G7xZnkvnGMPei5Yh_SUQ22EXiTZjqSlDn5wFhHfQGddmUF0gxl4UcFKb2KNzGeur4g1rvInLS7WKsDeBk-Pj880VZQgVoRBQvMRoabSES5E0qayGVBaC0Lmci5QqxlAmE5yxTPubOGxbHO0c9iITMtMxVrGx7CelEW7hiIyUIEM3EmJJ6SQWQ0QkcMug7xpjBSDuCyM84UHdZ3IXThymU17cwzgKPGvtNZs1djimBD-o1gJ3-ePYWthrfhSyFn0M_xqrpz2LDfi7dqflH7Ab7T8egHRAS9vw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mortality+impact+of+less-than-standard+therapy+in+older+breast+cancer+patients&rft.jtitle=Journal+of+the+American+College+of+Surgeons&rft.au=Yood%2C+Marianne+Ulcickas&rft.au=Owusu%2C+Cynthia&rft.au=Buist%2C+Diana+S+M&rft.au=Geiger%2C+Ann+M&rft.date=2008-01-01&rft.eissn=1879-1190&rft.volume=206&rft.issue=1&rft.spage=66&rft_id=info:doi/10.1016%2Fj.jamcollsurg.2007.07.015&rft_id=info%3Apmid%2F18155570&rft_id=info%3Apmid%2F18155570&rft.externalDocID=18155570
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1879-1190&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1879-1190&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1879-1190&client=summon